The LMNA gene contains 12 exons and encodes lamins A and C by alternative splicing within exon 10. While mutations in lamin A specific residues cause several diseases including lipodystrophy, progeria, muscular dystrophy, neuropathy, and cardiomyopathy, only three families with mutations in lamin C-specific residues are reported with cardiomyopathy, neuropathy, and muscular dystrophy so far. We now report two brothers with juvenile-onset generalized lipodystrophy due to a lamin C-specific mutation. The proband, a 23-year-old Caucasian male was reported to have generalized lipodystrophy at 3 weeks of age, developed diabetes, hypertriglyceridemia, hypertension and liver problems and died with complications of cirrhosis, and kidney failure. His younger brother, a 37-year-old Caucasian male developed generalized lipodystrophy around 2 years of age and was diagnosed with diabetes, hypertriglyceridemia, fatty liver, and hypertension at 36 years of age. Their father also died of end stage renal disease at age 52 years. Exome sequencing of the proband revealed an extremely rare missense heterozygous variant c.1711_1712CG>TC; p.(Arg571Ser) in LMNA which was confirmed by Sanger sequencing in both the patients. Interestingly, the mutation had no effect on mRNA splicing or relative expression of lamin A or C mRNA and protein in the lymphoblasts. Our observations suggest that mutant lamin C disrupts its interaction with other cellular proteins resulting in generalized lipodystrophy due to defective development and maintenance of adipose tissue.
This Caucasian male developed generalized loss of fat with muscular appearing arms and legs and prominent superficial veins around 3 weeks of age and was initially reported as having congenital generalized lipodystrophy (CGL 4200) (Agarwal et al., 2003) . Subsequently, he developed diabetes mellitus, hypertriglyceridemia, hypertension, and liver problems. He also had inguinal hernia that needed repair at 6 years of age. At age 22 years, his fasting blood glucose was 366 mg/dL; hemoglobin A1c, 9.3%; high density lipoprotein (HDL)-cholesterol, FIGURE 1 Clinical features of patient JGL100.5 at 36 years of age. Anterior (a) and lateral (b) views showing muscular extremities and generalized loss of subcutaneous fat. There is loss of subcutaneous fat and prominent calluses on both the soles (c) and palms (d) and prominent superficial veins in the lower leg (e). (f) Skin-fold thickness at various anatomical sites. The shaded bars represent the median, 10th and 90th percentile values of skin-fold thickness for normal adult males (Jackson & Pollock, 2004) . Majority of the measurements were below the 10th percentile. [Color figure can be viewed at wileyonlinelibrary.com] FIGURE 2 JGL Pedigree, location of the mutation in the LMNA gene and Lamin C protein, exome data, Sanger sequencing, and mRNA and protein expression in lymphoblasts. (a) JGL 100 pedigree showing both the affected patients. Circles denote females and squares represent males. The half-filled symbols represent the affected heterozygotes including the proband's father who was presumed affected but did not undergo genotyping. Unfilled symbols indicate the unaffected subjects. The mother of the proband had the wild-type alleles and did not carry the disease-causing variant. A diagonal line across a symbol indicates a deceased subject. The numbers above the symbols indicate the age of the subjects and besides the symbols indicate the pedigree number. (b) Illustration of LMNA gene depicting the location of mutation c.1711_1712CG > TC in our patients. The LMNA gene contains 12 exons and encodes lamins A and C by alternative splicing within exon 10. Exons 1 through 10 contain sequences encoding 566 amino acids that are shared by both the isoforms. Exons 11 and 12 contain sequences that are found in the transcript of lamin A, and 3′ region of exon 10 contains 18 nucleotides that encode 6 lamin C-specific residues. Boxes indicate exons and the lines in between them indicate the introns. Black and hatched regions indicate translated regions of exons, while white regions indicate 5′ and 3′ untranslated regions. Hatched regions indicate lamin A or lamin C specific exons. (c) Schematic structure of lamins A and C proteins. Both have identical structure throughout the NH 2 -terminal head, α-helical rod domain and proximal carboxy terminal region (blue color), but differ in their distal C-terminal amino acids (lamin C specific region is shown in red and lamin A specific region is shown in purple). Mutation p.(Arg 571Ser) in our patients lies in lamin C region. (d) Whole exome sequencing of patient 1 (JGL100.4) showing missense heterozygous variant NC_000001.10:g.156107547_156107548delCGinsTC (rs794728612); c.1711_1712CG > TC). Note that both the nucleotide substitutions are on the same allele ( Figure 2d ). (e) Chromatogram from Sanger sequencing showing the heterozygous 2-nucleotide substitution in the proband. The unaffected mother did not harbor the mutation. Arrows indicate the site of mutation. (f) The amplified PCR product from control lymphoblasts (N5900) and affected lymphoblasts (JGL 100.4) as analyzed on a 1% agarose gel stained with ethidium bromide. The amplified PCR products are of expected size and upon sequencing carry wild-type lamin A and C sequences. Shown also are the amplification of the housekeeping gene, 18S. (g) Immunoblot analysis for lamin A and lamin C proteins of total cellular lysate obtained from lymphoblasts of controls (N300, N5900) and affected subject (JGL100.4). Cellular lysates were loaded in increasing protein concentration and probed with anti-lamin A/C antibody raised against N-terminus of the protein. The same protein blot was stripped and re-probed with GAPDH antibody. In lymphoblasts, the expression of lamin A is less than that of lamin C. There was no difference in the relative expression of lamins A and C in the controls and the affected subject. [Color figure can be viewed at wileyonlinelibrary.com] 15 mg/dL; and triglycerides, 270 mg/dL. He developed cirrhosis and kidney failure resulting in death at 23 years of age.
| JGL100.5
This 37-year-old younger brother of the proband, developed generalized loss of subcutaneous fat at age 2 years ( Figure 1 and supplementary Figure S1 ). At age 36 years, he was diagnosed with diabetes, hypertriglyceridemia, fatty liver and hypertension, and was started on fish oil, metformin 1000 mg daily, losartan 50 mg daily, and carvedilol 25 mg daily. He underwent right hemi-thyroidectomy for thyroid nodules at age 36 years with biopsy consistent with autoimmune thyroiditis. He had an umbilical hernia repair at age 13 years, left eye corneal transplant at age 32 years for keratoconus and deviated nasal septum repair at age 36 years. He also had intermittent joint pains. He had an automobile accident at age 31 which required metal implants in left humerus, tibia, and fibula due to compound fractures. His two daughters, ages 6 and 2 years, are healthy. At age 36 years, his weight (Figure 1f ). His total body fat by dual energy X-ray absorptiometry (Discovery W, Hologic) was 10.5% (1%ile age matched). Body fat in the right upper extremity was 9.4%, in the right lower extremity was 8.6%, and in the trunk was 10.6%. His total bone mineral density (excluding left arm and left leg) was 1.35 g/cm 2 (mean ± SD for non-hispanic white males being 1.21 ± 0.106). Their father had loss of subcutaneous fat from the face in the photographs, but the extremities were not visualized. He also had premature coronary artery disease, hypertension, and kidney disease.
He was on dialysis for about 10 years and died at the age of 52 years.
Their 56-year-old mother was healthy (Figure 2a) .
| METHODS
The protocol was approved by Institutional Review Board of UT Southwestern. A written informed consent was obtained from both the patients and their mother and healthy control subjects. Genomic DNA was isolated from whole blood, and whole exome, and Sanger sequencing were performed (Supplementary Methods). Total RNA was extracted from lymphoblasts for mutational analysis using allele specific primers and expression studies using real-time PCR; and protein was extracted for immunoblotting (Supplementary methods).
| RESULTS
Initial Sanger sequencing of CGL genes, AGPAT2, and BSCL2, revealed no pathogenic variants. We followed this with whole exome sequencing and confirmed the lack of pathogenic variants in AGPAT2 
| DISCUSSION
We report the first patients with JGL with a lamin C-specific mutation.
Previously, Fatkin et al. (1999) reported a heterozygous c.1711C>A; p.
(Arg571Ser) mutation in a family presenting with relatively mild conduction system disease and dilated cardiomyopathy. The same variant was reported by Ng and Kaye (2013) in a 32-year-old female with atrial fibrillation. Her father had undergone cardiac transplantation for cardiomyopathy. A heterozygous c.1711C>T; p.(Arg571Cys) mutation, was reported in a 14-year-old male with overt neuropathy and myopathy, and his 54-year-old mother with subclinical peripheral nerve involvement by Benedetti et al. (2005) . These investigators did not report any lipodystrophy in affected patients.
While both c.1711C>A and c.1711_12CG>TC LMNA variants are predicted to cause p.(Arg571Ser), why there is marked contrast in the phenotypic manifestations associated with the two variants is unclear. We were unable to show any effects of c.1711_12CG>TC
LMNA variant on RNA splicing or relative expression of lamin A or C mRNA and protein in the lymphoblasts, however, whether this mutation affects the expression of lamins A or C in adipose tissue differently, will require further investigation. However, previous studies reveal equal expression of lamin A and C proteins in stromal vascular fraction or mature adipocytes from visceral and subcutaneous adipose tissue, indicating important role of lamin C in adipose tissue development, and maintenance (Lelliott et al., 2002; Peinado et al., 2010) .
In summary, our cases add to the phenotypic manifestations associated with alterations in lamin C-specific residues. In humans, lamin C may have a wider role in cellular biology and may specifically contribute to function of various tissues including adipose, renal, cardiac, skeletal muscle, and nerves. 
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